- Home
- GES vs ORKA Comparison
GES vs ORKA Comparison
Compare GES & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GES
- ORKA
- Stock Information
- Founded
- GES 1981
- ORKA 2004
- Country
- GES Switzerland
- ORKA United States
- Employees
- GES N/A
- ORKA N/A
- Industry
- GES Apparel
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GES Consumer Discretionary
- ORKA Health Care
- Exchange
- GES Nasdaq
- ORKA Nasdaq
- Market Cap
- GES 628.9M
- ORKA 354.2M
- IPO Year
- GES 1996
- ORKA N/A
- Fundamental
- Price
- GES $12.70
- ORKA $14.54
- Analyst Decision
- GES Buy
- ORKA Strong Buy
- Analyst Count
- GES 4
- ORKA 8
- Target Price
- GES $17.75
- ORKA $39.71
- AVG Volume (30 Days)
- GES 687.6K
- ORKA 362.2K
- Earning Date
- GES 08-27-2025
- ORKA 08-15-2025
- Dividend Yield
- GES 9.14%
- ORKA N/A
- EPS Growth
- GES N/A
- ORKA N/A
- EPS
- GES 0.10
- ORKA N/A
- Revenue
- GES $3,051,131,000.00
- ORKA N/A
- Revenue This Year
- GES $7.34
- ORKA N/A
- Revenue Next Year
- GES $3.20
- ORKA N/A
- P/E Ratio
- GES $135.81
- ORKA N/A
- Revenue Growth
- GES 9.02
- ORKA N/A
- 52 Week Low
- GES $8.48
- ORKA $5.49
- 52 Week High
- GES $24.64
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- GES 53.42
- ORKA N/A
- Support Level
- GES $11.99
- ORKA N/A
- Resistance Level
- GES $13.63
- ORKA N/A
- Average True Range (ATR)
- GES 0.50
- ORKA 0.00
- MACD
- GES -0.05
- ORKA 0.00
- Stochastic Oscillator
- GES 43.29
- ORKA 0.00
About GES Guess? Inc.
Guess? Inc designs, markets distributes, and licenses contemporary apparel and accessories that reflect European fashion sensibilities and American Lifestyle under brands including Guess, Marciano, and G by Guess. The company has five reportable segments: Americas Retail, Americas Wholesale, Europe, Asia, and licensing. Geographically, the company derives maximum revenue from the United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.